Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)

posted 25th September 2024

Posted 4 months ago

By NHP Office

Features New Therapies News & Updates
Pfizer Withdraws OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD)

On 25th September 2024, Pfizer announced its voluntarily withdrawing of all lots of OXBRYTA ® (Voxelotor) for the treatment of sickle cell disease (SCD), in all markets where it is approved.

This announcement was wholly unexpected by the NHP members and many international colleagues. The panel appreciates this will have a profound impact on patients currently benefiting from this drug. Amidst many concerns, including the negative trend of new therapies in the Haemoglobinopathy landscape, the panel awaits further information and guidance from Pfizer.